GPCR
Structure TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Bull case assumes successful clinical readouts, one or more strategic partnerships, and meaningful uptake of lead oral GPCR-targeted therapy, driving re-rating toward peers and multiples seen in commercial-stage specialty biotech.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.6.
What can break
Capital raise dilution
Momentum
86
Value
41
Sentiment
15
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $32.00 · Bull $45.00 · Bear $18.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-31 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $106.53
Why
Momentum86 · Δ7d -4.6
Value41 · Δ7d +0.1
Sentiment15 · Δ7d +5.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
86
26% active weight
Current posture
7d trendSoftening
Δ7d
-4.6
Δ21d
+20.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
15
34% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
+3.5
Why this grade
Composite grade D. Momentum 85.8 / Value 41.1 / Sentiment 14.5
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$3.51B
Beta
-
Shares Out
71.07M
P/E (TTM) · Derived
-20.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-17.76
Rev YoY
-
EPS YoY
+28.6%
Gross Margin
-
Op Margin
-
Net Debt
-$1.44B
Current Ratio
26.16
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology